DCAT Value Chain Insights’ Production to Prescription
DCAT
51 episodes
2 weeks ago
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
Incorporating Sustainability into the Bio/Pharma Supply Chain: Where Does the Industry Stand?
DCAT Value Chain Insights’ Production to Prescription
15 minutes
3 years ago
Incorporating Sustainability into the Bio/Pharma Supply Chain: Where Does the Industry Stand?
A newly released DCAT benchmarking study examines the targets and progress made by bio/pharma companies and suppliers in reaching their sustainability goals. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Sustainability and the bio/pharma supply chainKey finding: External stakeholders drive effortsKey finding: Supply-chain sustainability lags internal effortsKey finding: Measuring achievement a major challengeK...
DCAT Value Chain Insights’ Production to Prescription
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
